Close Menu
Daily Guardian
  • Home
  • News
  • Politics
  • Business
  • Entertainment
  • Lifestyle
  • Health
  • Sports
  • Technology
  • Climate
  • Auto
  • Travel
  • Web Stories
What's On

Rent or Buy a Water Purifier for a One-Year Delhi Stay in 2026: ₹4,788 in Rent Against a ₹15,000 Purchase and Up to ₹6,000 in Yearly Upkeep on Plans Like Rentomojo's

September 27, 2026

B.C. Conservative leader ‘ready to rock’

September 26, 2026

Apple hit with $5.7 billion in damages over haptic patents

September 26, 2026

4 killed after helicopter crashes in field near Montreal

September 26, 2026

Lawyer wins case against multinational firm behind day school settlement

September 26, 2026
Facebook X (Twitter) Instagram
Finance Pro
Facebook X (Twitter) Instagram
Daily Guardian
Subscribe
  • Home
  • News
  • Politics
  • Business
  • Entertainment
  • Lifestyle
  • Health
  • Sports
  • Technology
  • Climate
  • Auto
  • Travel
  • Web Stories
Daily Guardian
Home » Human Microbiome Research Report 2025: Market to Reach $1.52 Billion by 2030, Rising at a CAGR of 16.28% – Global Trends, Opportunities, and Forecast, 2020-2030F
Press Release

Human Microbiome Research Report 2025: Market to Reach $1.52 Billion by 2030, Rising at a CAGR of 16.28% – Global Trends, Opportunities, and Forecast, 2020-2030F

By News RoomNovember 19, 20254 Mins Read
Human Microbiome Research Report 2025: Market to Reach .52 Billion by 2030, Rising at a CAGR of 16.28% – Global Trends, Opportunities, and Forecast, 2020-2030F
Share
Facebook Twitter LinkedIn Pinterest Email

Dublin, Nov. 19, 2025 (GLOBE NEWSWIRE) — The “Human Microbiome Market – Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F” report has been added to ResearchAndMarkets.com’s offering.

The Human Microbiome Market was valued at USD 0.62 Billion in 2024, and is expected to reach USD 1.52 Billion by 2030, rising at a CAGR of 16.28%

The Global Human Microbiome Market is experiencing a significant transformation, fueled by growing scientific recognition of the microbiome’s impact on human health and disease, along with increasing investments from pharmaceutical and biotechnology firms. This market encompasses the development of diagnostics, therapeutics, and healthcare solutions aimed at leveraging or modifying the human microbiota comprising trillions of microorganisms that inhabit the human body for improved medical outcomes.

Key Market Drivers

Increased Application in Cancer Treatment

Research has demonstrated that the human microbiome plays a crucial role in modulating immune responses, which directly impacts the efficacy of immunotherapies and chemotherapy. Certain gut microbiota strains have been found to enhance the effectiveness of immune checkpoint inhibitors, leading to improved patient outcomes. Biotech firms and pharmaceutical companies are investing in microbiome-derived drugs that can be used as adjunct therapies to traditional cancer treatments. These therapies aim to reduce treatment-related toxicity, improve drug absorption, and enhance immune system resilience.

The surge in clinical trials exploring microbiome-based interventions for cancer treatment is accelerating market growth. Studies are investigating how gut microbiota composition influences cancer progression and response to therapy. Rajiv Gandhi Cancer Institute and Research Centre (RGCIRC) has established itself as a premier clinical trial site, earning recognition from leading global cancer research institutions and pharmaceutical companies. With a track record of participation in over 300 national and international clinical trials, the center plays a pivotal role in advancing oncology research and innovative cancer therapies across diverse cancer types. Leading biotech firms and research institutions are forming strategic partnerships to develop microbiome-based cancer solutions. Increased funding from government agencies and private investors is driving innovation in microbiome therapeutics.

The integration of microbiome profiling into precision oncology is enabling personalized treatment plans tailored to individual patients. AI-driven microbiome analysis is helping identify biomarkers that predict cancer treatment responses. Regulatory bodies are recognizing the potential of microbiome-based therapies, leading to faster approvals and standardization efforts. The market is witnessing expansion into emerging economies, where cancer prevalence is rising.

Key Market Challenges

Scientific Complexity and Limited Understanding of Microbiome Functions

One of the most fundamental challenges impeding market growth is the incomplete and complex understanding of the human microbiome’s structure, function, and interactions with host physiology. Despite major research advancements, scientists still face difficulties in: Differentiating between beneficial, neutral, and harmful microbes, Understanding causal relationships between microbiome imbalances and specific diseases, Establishing universal biomarkers or reference ranges for “healthy” microbiota.

This scientific uncertainty limits the ability of researchers and companies to design effective, targeted, and reproducible microbiome-based therapies. Moreover, it complicates clinical trial design and makes it harder to validate efficacy, slowing product development and investor confidence.

Key Market Trends

Shift Toward Personalized Microbiome-Based Therapies

The most significant trends fueling market growth is the rapid evolution of personalized medicine powered by microbiome insights. As scientific understanding of the human microbiome deepens, it is becoming increasingly clear that microbial compositions vary significantly across individuals. This has led to a paradigm shift from generalized probiotic or therapeutic approaches toward personalized microbiome interventions, including: Tailored probiotics and synbiotics based on individual gut flora, Microbiome profiling and diagnostics to guide treatment decisions, Customized dietary recommendations to optimize gut health and disease prevention.

This trend aligns with the broader healthcare movement toward precision medicine, offering more effective, safer, and targeted interventions. As genomic sequencing and microbiome mapping technologies become more accessible and affordable, personalized microbiome-based therapies are poised to redefine patient care.

Key Attributes:

Report Attribute Details
No. of Pages 182
Forecast Period 2024 – 2030
Estimated Market Value (USD) in 2024 $0.62 Billion
Forecasted Market Value (USD) by 2030 $1.52 Billion
Compound Annual Growth Rate 16.2%
Regions Covered Global


Report Scope:

Key Market Players

  • Enterome Bioscience SA
  • Yakult Honsha Co. Ltd.
  • 4 D Pharma
  • Evelo Biosciences
  • Seres Therapeutics Inc.
  • Vedanta Biosciences
  • Second Genome Inc.
  • Quantibiome
  • Rebiotix Inc.
  • Microbiome Therapeutics LLC

Human Microbiome Market, By Product:

  • Prebiotics
  • Probiotics
  • Medical Food
  • Supplements
  • Others

Human Microbiome Market, By Application:

Human Microbiome Market, By Disease:

  • Infectious Disease
  • Endocrine and Metabolic Disorders
  • Gastrointestinal Diseases
  • Cancer
  • Others

Human Microbiome Market, By Technology:

  • Genomics
  • Proteomics
  • Metabolomics

Human Microbiome Market, By Type:

  • FMT
  • Peptide
  • Live Biotherapeutic Product
  • Others

Human Microbiome Market, By Region:

  • North America
  • United States
  • Canada
  • Mexico
  • Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
  • Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • South America
  • Brazil
  • Argentina
  • Colombia
  • Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

For more information about this report visit https://www.researchandmarkets.com/r/c9nc9h

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.


Share. Facebook Twitter Pinterest LinkedIn Tumblr Email

Keep Reading

Rent or Buy a Water Purifier for a One-Year Delhi Stay in 2026: ₹4,788 in Rent Against a ₹15,000 Purchase and Up to ₹6,000 in Yearly Upkeep on Plans Like Rentomojo's

BABA 9-DAY DEADLINE ALERT: Alibaba Group Holding Limited Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit Before October 5, 2026 Lead Plaintiff Deadline

PNR 6-DAY DEADLINE ALERT: Pentair plc Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit Before October 2, 2026 Lead Plaintiff Deadline

Upcoming Blaze Wilde Podcast on Snapchat Exploring Pop Culture, Politics, and Life Between Arab and American Culture

Yan’an Apple Price Index Debuts in Shanghai: Unlocking Fair, Quality-Based Fruit Pricing

WSE INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Wise Group plc (WSE) Investors of Securities Class Action Lawsuit Deadline on September 29, 2026

Sixthfin Financial Close Management Software Supports UK Internal Control Evidence for Provision 29 and ECCTA Failure-to-Prevent-Fraud Across 38 ERP Systems in 2026

RXT INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Rackspace Technology Investors of Securities Class Action Lawsuit Deadline on September 28, 2026

PNR INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Pentair (PNR) Investors of Securities Class Action Lawsuit Deadline on October 2, 2026

Editors Picks

B.C. Conservative leader ‘ready to rock’

September 26, 2026

Apple hit with $5.7 billion in damages over haptic patents

September 26, 2026

4 killed after helicopter crashes in field near Montreal

September 26, 2026

Lawyer wins case against multinational firm behind day school settlement

September 26, 2026

Latest News

OpenAI pauses training of its ‘most capable models’

September 26, 2026

Kids turned the comment section of an NPR podcast into a group chat

September 26, 2026

BABA 9-DAY DEADLINE ALERT: Alibaba Group Holding Limited Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit Before October 5, 2026 Lead Plaintiff Deadline

September 26, 2026
Facebook X (Twitter) Pinterest TikTok Instagram
© 2026 Daily Guardian Canada. All Rights Reserved.
  • Privacy Policy
  • Terms
  • Advertise
  • Contact

Type above and press Enter to search. Press Esc to cancel.

Go to mobile version